Macquarie Group
TCRT icon

Macquarie Group’s Alaunos Therapeutics TCRT Stock Holding History

Macquarie Group’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-187
Closed -$18 – 2624
2022
Q1 		$18 Hold
187
– – ﹤0.01% 2418
2021
Q4 		$31K Hold
187
– – ﹤0.01% 2293
2021
Q3 		$51K Buy
187
+145
+345% +$44.3K ﹤0.01% 2233
2021
Q2 		$16K Hold
42
– – ﹤0.01% 2407
2021
Q1 		$22K Sell
42
-12
-22% -$7.47K ﹤0.01% 2258
2020
Q4 		$21K Hold
54
– – ﹤0.01% 2213
2020
Q3 		$21K Hold
54
– – ﹤0.01% 2158
2020
Q2 		$27K Buy
+54
New +$24.1K ﹤0.01% 2093

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Macquarie Group's TCRT Position: Q2 2022 in Review

Macquarie Group sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 187 shares — an estimated $18 sold.

Macquarie Group first reported a position in TCRT in Q2 2020 and held it in 8 quarters. The position peaked at $51K in Q3 2021. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

  • Macquarie Group reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Macquarie Group sold 187 Alaunos Therapeutics shares in Q2 2022, an estimated $18.
  • Macquarie Group first reported a position in Alaunos Therapeutics in Q2 2020 and held it in 8 quarters.
  • Macquarie Group's Alaunos Therapeutics position peaked at $51K in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Macquarie Group's 13F filing for Q2 2022, filed 15 Aug 2022.